Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_1
2
67%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Other(3)

Detailed Status

unknown3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

unknown3100%

Recent Activity

0 active trials
Showing 3 of 3
unknown

Image Characteristic and Longitudinal Follow up of 18F-PMPBB3 (APN-1607) PET for Progressive Supranuclear Palsy

NCT04541836
unknownphase_1

A Noval Tau Tracer in Young Onset Dementia

NCT04248270
unknownphase_1

To Study the Pathophysiological Features of Multiple Sclerosis

NCT04242056

Clinical Trials (3)

Showing 3 of 3 trials
NCT04541836

Image Characteristic and Longitudinal Follow up of 18F-PMPBB3 (APN-1607) PET for Progressive Supranuclear Palsy

Unknown
NCT04248270Phase 1

A Noval Tau Tracer in Young Onset Dementia

Unknown
NCT04242056Phase 1

To Study the Pathophysiological Features of Multiple Sclerosis

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3